Activities per year
Abstract
Androgen-deprivation therapy (ADT) is well established as the standard of care in metastatic prostate cancer (PCa) management; however, ADT has significant adverse effects (AEs) that must be addressed. This review aims to highlight opportunities to mitigate AEs of ADT and explore alternatives in PCa management. Specifically, we discuss behavioral and pharmacologic strategies for mitigating ADT AEs as well as ADT-sparing approaches for hormone-sensitive and castration-resistant PCa. Equipped with effective mitigation strategies and possible alternatives, clinicians and researchers can optimize health-related quality of life for patients currently receiving ADT for PCa and consider treatments that spare patients from AEs of ADT.
| Original language | English |
|---|---|
| Article number | e433126 |
| Journal | American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting |
| Volume | 44 |
| Issue number | 3 |
| Early online date | 24 May 2024 |
| DOIs | |
| Publication status | Published - 24 Jun 2024 |
| Event | ASCO Annual Meeting 2024 - Chicago, United States Duration: 31 May 2024 → 4 Jun 2024 |
Keywords
- Humans
- Male
- Androgen Antagonists/therapeutic use
- Prostatic Neoplasms/drug therapy
- Quality of Life
- Antineoplastic Agents, Hormonal/therapeutic use
- Disease Management
Access to Document
Fingerprint
Dive into the research topics of 'Balancing Hormone Therapy: Mitigating Adverse Effects of Androgen-Deprivation Therapy and Exploring Alternatives in Prostate Cancer Management'. Together they form a unique fingerprint.Prizes
-
Prostate Cancer Foundation Young Investigator Award
Sachdeva, A. (Recipient), 2022
Prize: Fellowship awarded competitively
Activities
- 1 Invited talk
-
Bone Resorptive Agents and Their Appropriate Use and Timing
Sachdeva, A. (Speaker)
2 Jun 2024Activity: Talk or presentation › Invited talk › Research